Supplementary Table 1. Crude cost items by lipid goal attainments.
| Lipid goal attainments | N | All management cost |
All management cost excluding all the cardio-related cost |
Cardiovascular-related inpatient cost |
Cardiovascular-related outpatient cost |
Cardiovascular-related inpatient and outpatient cost |
Lipid-lowering therapy (statins and other lipid-lowering drugs) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HKD | (USD) | HKD | (USD) | HKD | (USD) | HKD | (USD) | HKD | (USD) | HKD | (USD) | ||
| Full sample (n = 4638) | 4638 | 84021.88 | (10772.04) | 37598.98 | (4820.38) | 34294.78 | (4396.77) | 12010.26 | (1539.78) | 45954.70 | (5891.63) | 764.78 | (98.05) |
| Endpoint LDL-C achieving the goal of 2.6 mmol/L | |||||||||||||
| Not at goal | 950 | 85979.66 | (11023.03) | 44935.63 | (5760.98) | 29061.01 | (3725.77) | 11835.23 | (1517.34) | 40731.76 | (5222.02) | 675.92 | (86.66) |
| At goal | 3688 | 83516.90 | (10707.30) | 35706.62 | (4577.77) | 35644.75 | (4569.84) | 12055.40 | (1545.56) | 47301.87 | (6064.34) | 787.70 | (100.99) |
| Endpoint LDL-C achieving the goal of 1.8 mmol/L | 4638 | ||||||||||||
| Not at goal | 2962 | 82682.57 | (10600.33) | 38365.84 | (4918.70) | 32431.62 | (4157.90) | 11701.03 | (1500.13) | 43767.36 | (5611.20) | 640.65 | (82.14) |
| At goal | 1676 | 86388.86 | (11075.49) | 36243.71 | (4646.63) | 37587.55 | (4818.92) | 12556.75 | (1609.84) | 49820.39 | (6387.23) | 984.14 | (126.17) |
| Endpoint LDL-C achieving the goal of 2.0 mmol/L | 4638 | ||||||||||||
| Not at goal | 2382 | 83143.60 | (10659.44) | 39861.10 | (5110.40) | 31382.20 | (4023.36) | 11679.77 | (1497.41) | 42828.18 | (5490.79) | 635.40 | (81.46) |
| At goal | 2256 | 84949.21 | (10890.92) | 35210.52 | (4514.17) | 37370.04 | (4791.03) | 12359.20 | (1584.51) | 49255.83 | (6314.85) | 901.39 | (115.56) |
| Endpoint LDL-C achieving the reduction of ≥ 50% | 4182 | ||||||||||||
| Not at goal | 3549 | 85297.01 | (10935.51) | 38541.63 | (4941.24) | 34225.65 | (4387.90) | 12504.82 | (1603.18) | 46712.21 | (5988.74) | 638.31 | (81.83) |
| At goal | 633 | 82223.61 | (10541.49) | 33773.27 | (4329.91) | 37244.65 | (4774.95) | 11205.70 | (1436.63) | 48450.35 | (6211.58) | 1484.50 | (190.32) |
| Endpoint LDL-C category | 4638 | ||||||||||||
| > 2.6 mmol/L | 950 | 85979.66 | (11023.03) | 44935.63 | (5760.98) | 29061.01 | (3725.77) | 11835.23 | (1517.34) | 40731.76 | (5222.02) | 675.92 | (86.66) |
| 1.8–2.6 mmol/L | 2012 | 81123.37 | (10400.43) | 35258.99 | (4520.38) | 34025.58 | (4362.25) | 11637.57 | (1492.00) | 45202.89 | (5795.24) | 623.98 | (80.00) |
| < 1.8 mmol/L | 1676 | 86388.86 | (11075.49) | 36243.71 | (4646.63) | 37587.55 | (4818.92) | 12556.75 | (1609.84) | 49820.39 | (6387.23) | 984.14 | (126.17) |
| Analyzed sample (n = 4625) | |||||||||||||
| Latest LDL-C before MACE achieving the goal of 2.6 mmol/L | 4625 | 83927.13 | (10759.89) | 37691.60 | (4832.26) | 34133.48 | (4376.09) | 12040.65 | (1543.67) | 46010.37 | (5898.76) | 766.83 | (98.31) |
| Not at goal | 981 | 89092.49 | (11422.11) | 46677.64 | (5984.31) | 30467.26 | (3906.06) | 11909.24 | (1526.83) | 42298.15 | (5422.84) | 714.08 | (91.55) |
| At goal | 3644 | 82536.57 | (10581.61) | 35272.47 | (4522.11) | 35120.47 | (4502.62) | 12076.03 | (1548.21) | 47009.73 | (6026.89) | 781.03 | (100.13) |
| Latest LDL-C before MACE achieving the goal of 1.8 mmol/L | 4625 | ||||||||||||
| Not at goal | 2983 | 83178.75 | (10663.94) | 38433.26 | (4927.34) | 32886.29 | (4216.19) | 11764.48 | (1508.27) | 44578.84 | (5715.24) | 667.50 | (85.58) |
| At goal | 1642 | 85286.70 | (10934.19) | 36344.23 | (4659.52) | 36399.25 | (4666.57) | 12542.37 | (1608.00) | 48611.00 | (6232.18) | 947.28 | (121.45) |
| Latest LDL-C before MACE achieving the goal of 2.0 mmol/L | 4625 | ||||||||||||
| Not at goal | 2411 | 84468.93 | (10829.35) | 40280.41 | (5164.16) | 32329.59 | (4144.82) | 11749.64 | (1506.36) | 43994.11 | (5640.27) | 658.84 | (84.47) |
| At goal | 2214 | 83337.12 | (10684.25) | 34872.44 | (4470.83) | 36097.89 | (4627.93) | 12357.57 | (1584.30) | 48206.02 | (6180.26) | 884.43 | (113.39) |
| Latest LDL-C before MACE achieving the reduction of ≥ 50% | 4180 | ||||||||||||
| Not at goal | 3547 | 85314.22 | (10937.72) | 38563.37 | (4944.02) | 34233.07 | (4388.86) | 12511.87 | (1604.09) | 46738.55 | (5992.12) | 652.17 | (83.61) |
| At goal | 633 | 82223.61 | (10541.49) | 33773.27 | (4329.91) | 37244.65 | (4774.95) | 11205.70 | (1436.63) | 48450.35 | (6211.58) | 1454.30 | (186.45) |
| Latest LDL-C before MACE category | 4625 | ||||||||||||
| > 2.6 mmol/L | 981 | 89092.49 | (11422.11) | 46677.64 | (5984.31) | 30467.26 | (3906.06) | 11909.24 | (1526.83) | 42298.15 | (5422.84) | 714.08 | (91.55) |
| 1.8–mmol/L | 2002 | 80280.96 | (10292.43) | 34393.44 | (4409.41) | 34071.63 | (4368.16) | 11693.55 | (1499.17) | 45696.40 | (5858.51) | 644.68 | (82.65) |
| < 1.8 mmol/L | 1642 | 85286.70 | (10934.19) | 36344.23 | (4659.52) | 36399.25 | (4666.57) | 12542.37 | (1608.00) | 48611.00 | (6232.18) | 947.28 | (121.45) |
MACE indicates major adverse cardiovascular events; LDL-C, low-density lipoprotein cholesterol; HKD, Hong Kong Dollars; USD, United States Dollars.